SLC5A2 and type 2 diabetes mellitus: This case highlights the potential of combining a DPP-4 inhibitor (sitagliptin) with an SGLT2 inhibitor (empagliflozin), which may help improve glycemic control in a patient with CMT complicated by type 2 diabetes and appears not to have compromised skeletal muscle mass.